Ultima Genomics to Launch UG 100™ System and Present Data at AGBT
Ultima Genomics to Launch UG 100™ System and Present Data at AGBT
Robust scientific program around launch of UG 100™ featuring Early Access customers and collaborators
Highlights new data and the unique benefits of the UG 100™ Platform across several key applications
FREMONT, Calif.--(BUSINESS WIRE)--Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput sequencing architecture, will present product and commercial launch details for the UG 100™ system as the Gold Sponsor at the Advances in Genome Biology and Technology (AGBT) General Meeting Feb. 5-8, 2024, in Orlando, FL.
The Gold Sponsor workshop will also include presentations by customers and collaborators from multiple leading institutions including:
- Stacey Gabriel, Ph.D., Executive Vice President of Platforms and Scientific Execution, Institute Scientist, Broad Institute of MIT and Harvard
- Aziz Al’Khafaji, Ph.D., Associate Director, Technology Development – Genomics Platform, Broad Institute of MIT and Harvard
- Rahul Satija, D.Phil., Core Faculty Member, New York Genome Center
- Will Salerno, Ph.D., Executive Director of Genome Informatics & Data Engineering, Regeneron Pharmaceuticals
- Dan Landau, M.D., Ph.D., Professor of Physiology and Biophysics, Weill Cornell Medical College
Join Ultima for a series of talks and poster sessions, including:
Monday, February 6:
Sadie VanHorn, Washington University, St. Louis will present “High-resolution single-cell lineage tracing at scale reveals reprogramming dynamics” at 6:40 pm in Palms Ballroom II & III
Tuesday, February 6:
Julian Hess, Broad Institute of MIT and Harvard will present “High accuracy somatic variant calling on Ultima Genomics facilitates detailed phylogenetic reconstruction across 303 metastatic tumor samples” at 11:05 am in Palms Ballroom II & III
Ultima Genomics will be hosting the Gold Sponsor Workshop and Lunch entitled “Genomics unleashed: the $100 genome and beyond” at 12:00 pm in Grand Sierra Ballroom D&E
Ultima technology will be featured in three posters during the Tuesday poster session at 1:30 pm in Palms Ballroom I:
- 101 - Advancing cancer genomics with cost-effective whole genome sequencing: somatic variant calling using the UG 100 platform, by Hila Benjamin of Ultima Genomics
- 518 - A continued evaluation of the Ultima Genomics UG100 platform: operational advancements and new methods for ancient DNA, single-cell, and methylation applications, by Matthew Coole of the Broad Institute
- 592 - Integration of mostly-natural sequencing by synthesis with multiple single cell and spatial assays: 10X Flex, Visium and immune profiling, by Gila Yanai of Ultima Genomics
Wednesday, February 7:
Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing a New Era: Part Per Million Detection Accuracy with ppmSeq™️ Technology” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C
Ultima technology will be featured in three posters during the Wednesday poster session at 4:45 pm in Palms Ballroom I:
- 529 - Balanced-strand sequencing enables massively scalable duplex variant calling of ultra-low frequency mutations, by Alexandre Cheng of the New York Genome Center
- 557 - Assessment of Ultima Genomics $100 genome for whole genome sequencing-based cancer diagnostics, by Edwin Cuppen of the Hartwig Medical Foundation
- 625 - Scalable Dual Indexed Single Cell WGS on Ultima Genomics, by Andrew Wicks of the New York Genome Center
Thursday, February 8:
Ultima Genomics will be hosting a Technical Breakfast Workshop entitled “Introducing the Next Wave of Single Cell and Omics at Scale” at 8:00 am in Ultima Suite, Grand Sierra Ballroom C
Dennis Yuan, New York Genome Center will present “High-throughput miniaturized-automated workflow for joint high-depth whole genome and whole transcriptome sequencing of thousands of human primary cells” at 3:00 pm in Palms Ballroom II & III
A full schedule of Ultima Genomics events at AGBT can be found here.
About Ultima Genomics
Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.
